Adoptive therapy with CAR redirected T cells: the challenges in targeting solid tumors

Area of Science:

• Oncology
• Immunotherapy
• Cellular Therapy

Background:

• Chimeric antigen receptor (CAR)-modified T cells have achieved remarkable success in treating leukemia and lymphoma.
• CAR T-cells offer potential for broad cancer treatment due to their engineered specificity, independent of natural T-cell receptors and MHC presentation.
• This engineered specificity allows targeting of virtually any cell surface antigen.

Purpose of the Study:

• To discuss the challenges and strategies for applying CAR T-cell therapy to solid tumors.
• To explore novel approaches for enhancing CAR T-cell efficacy against solid tumor malignancies.

Main Methods:

• Review and discussion of current limitations in CAR T-cell therapy for solid tumors.
• Exploration of advanced CAR T-cell engineering strategies.

Main Results:

• CAR T-cell therapy faces specific challenges when targeting solid tumors compared to hematological malignancies.
• Strategies such as targeting tumor stroma are critical for therapeutic success in solid tumors.
• The development of TRUCK cells (T cells with inducible payload release) is a promising future direction.

Conclusions:

• While CAR T-cell therapy has revolutionized blood cancer treatment, its application to solid tumors requires overcoming significant hurdles.
• Innovative strategies, including targeting the tumor microenvironment and employing advanced CAR T-cell designs, are essential for future clinical success in solid tumors.